Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection

Conclusions In patients with MPM, higher amatuximab exposure in combination with chemotherapy was shown to be associated with longer OS, supporting evaluation of more frequent dosing in future trials to achieve higher exposure and subsequently longer OS. (Source: Cancer Chemotherapy and Pharmacology)

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=167253242&cid=c_409_6_f&fid=33439&url=http%3A%2F%2Flink.springer.com%2F10.1007%2Fs00280-016-2984-z